here debug-> :lcxx11655

BiotechInvesting News

Your trusted source for investing success


Request an Investor Kit: Q BioMed

By completing this form, you are giving consent to receive email from Q BioMed. And remember you can unsubscribe at any time.

This profile is part of a investor education campaign. The profile provides detailed information which was sourced and approved by Q BioMed in order to help investors make better investment decisions. The Company’s support of Investing News Network ensures we can continue to bring you unbiased, independent news and information.

Life Science Investing News Featured Stock

Q BioMed - Bridging the Gap between Private and Public BioMed Acceleration

Q BioMed – Bridging the Gap between Private and Public BioMed Acceleration


Q BioMed Inc. (OTCQB:QBIO) is a biomedical company focused on licensing and acquiring strategic assets across a broad spectrum of biotech and healthcare related sectors for acceleration and development. The company provides these target assets with the capital resources, developmental support and clinical expertise needed to bring them to market or to a significant value inflection point.

Q BioMed helps link small and orphan biotech development companies with the capital market. One such company is Mannin Research Inc. which is focused on the discovery, development and commercialization of first-in-class therapeutics for vascular diseases. The first product under development in this technology platform is a nanofiber eye drop for treating the root cause of glaucoma, a disease affecting more than 60 million people worldwide.

In addition, in June 2016, Q BioMed announced it had entered into a definitive exclusive licensing agreement with a private U.S. company for an FDA-approved cancer palliative treatment. The drug is expected to generate revenue within the first year post-closing. The addition of a revenue asset to the company’s portfolio places Q BioMed in a class above the majority of its small-cap biotech peers and mitigates investment risk for Q BioMed shareholders.

“We have structured a landmark deal for the worldwide exclusive license and right to acquire the drug outright once it starts making sales,” commented Denis Corin, CEO of Q BioMed. “We’re very excited to have a revenue ready asset in the portfolio and we think there is a significant opportunity to grow not only the revenue but also expand the label on this drug into the therapeutic market.”

More information will be forthcoming following the closing of the transaction which is expected to be in mid July.

Investment Highlights

  • Accelerated development from the provision of capital, management and advisory expertise
  • Medical and Biotech market experiencing an unprecedented bull market with Biotech Index up 300 percent since the Financial Crisis
  • Inelastic demand for better drugs and more competitive access to those drugs
  • Diversified risk and shared success in multiple pipelines and sectors
  • Current Drug (Man 01) has massive market appeal and demand
  • Pending near-term revenue ready FDA drug in pipeline represents a milestone for the company
  • Additional target assets for acquisition in 2016 may include implantable post cataract lens, CAR T-Cell immunotherapy, a rare tropical disease drug and among others
  • Low float, tightly held with high percent management
  • Looking to uplist to NASDAQ in Q1 2017

Business Model

Q BioMed - Bridging the Gap between Private and Public BioMed Acceleration

Q BioMed’s business model allows the company to grow its asset pipeline with multiple assets in different stages of the product development life cycle. Once identified, assets undergo strict due diligence by the company’s key opinion leaders and advisory board. Ideal acquisition targets are preferably clinical stage, near value inflection or near revenue companies.

Along with capital, the company brings the technological and pharmaceutical experience of its clinical advisors to those assets to help accelerate development. “We’re not just providing capital, we’re providing the expertise to bring these products to major value inflection or even to market,” stated CEO DenisCorin.

A diverse asset pipeline also builds shareholder value and mitigates risk. “As an investor you’re not investing in one technology or asset and then left waiting for a binary event like an FDA approval or Phase 1 clinical data, with the only PR a notice of the CEO making another presentation at an investor conference,” explained Denis Corin. “With only one asset there is very little product development news flow; however with multiple assets in our pipeline in different stages of the development life cycle we anticipate constant news flow as milestones are met.. This is a unique opportunity for investors to come along for the ride as we advance the assets in our pipeline.”

Pending Near-Term Revenue Ready Asset: FDA-Approved Cancer Palliation Drug

We are very excited about the potential of this deal and look forward to bringing this transaction to fruition and thereby delivering significant value to all stakeholders, including the patients in need of this drug.Denis Corin, CEO of Q BioMed.

Q BioMed’s latest acquisition is an exclusive license for a FDA-approved drug for the treatment of pain associated with metastatic bone cancer. The drug is pending near-term revenue ready.

Cancer palliation and therapeutics represent multi-billion dollar markets. Q BioMed anticipates revenue for this drug to reach $1.5 million in the first year with the opportunity to grow revenues as high as $10 million or more in three to five years for this indication.

“While it’s great to underpin our portfolio with a revenue producer, we also think there is some significant upside in the expansion of the label on this asset,” said CEO Denis Corin. The company believes there is significant upside potential for label expansion into the Therapeutic market, which could create a $1 billion opportunity within the next two to three years.

MAN-01 Glaucoma Drug

Q BioMed has a License and Purchase Option Agreement with Mannin Research which grants the company a worldwide, exclusive license with the option to acquire Mannin’s platform assets for Glaucoma and other indications. The first product under development in this platform is MAN-01—an early stage pre-clinical asset with the potential to treat Primary Open Angle Glaucoma at the root cause by targeting abnormal vessels within the eye.

In Q2 2016, Mannin Research initiated pre-clinical optimization of MAN-01 for topical application in the form of an easy to administer nanofiber eye drop that contains the chemical tools needed to repair the canal —a much less invasive treatment than what is currently available to patients.

Market for Glaucoma Treatment

Globally, ophthalmology treatments represent a $23 billion market. Glaucoma therapeutics is one of its largest segments accounting for $5 billion annually in the U.S., Europe and Japan markets alone. The market for glaucoma therapeutics is growing and is expected to reach 80 million patients worldwide by 2020, according to the World Health Organization.

What Causes Glaucoma?

Glaucoma is caused by increased intraocular pressure (IOP) within the eye resulting in damage to the ocular nerve. One of the main causes for IOP is either a blocked or a defective specialized blood vessel known as the Schlemm’s Canal. The canal is a part of the body’s lymphatic system and serves as the major drainage pathway for fluid from the front of the eye and is responsible for 70 to 90 percent of fluid drainage in the eye.

Q BioMed - Bridging the Gap between Private and Public BioMed Acceleration

Blockage or an irregularity in this drainage pathway leads to IOP which overtime damages the nerves of the eye leading to blindness. Researchers have identified the Tie2/TEK receptor and the growth factor angiopoietin as the molecular building blocks for normal growth and development of the Schlemm’s Canal. Individuals lacking one of these essential building blocks often have a small or non-existent canal.

“Just imagine if we could grow a bigger Schlemm’s canal in anybody with glaucoma to lower the pressure in the eye. That’s what we’re hoping for with this new eye drop.” Dr. Susan Quaggin, Mannins Chief Scientific Officer

Currently, there is no cure for glaucoma and the current therapies and surgical procedures are not wholly effective and often painful. The market is ready for a new treatment option and if successful MAN-01 would be the first new drug for this indication brought to market in more than twenty years.

Having identified the building blocks of the Schlemm’s canal, Mannin’s researchers are now working to perfect the drug to treat the cause of glaucoma at the cellular level. MAN-01 is designed to repair the normal flow of fluid in the eye and effectively reduce IOP.

“Recent work in the lab underscores the essential role of Angpt-Tie2/TEK signaling for development of the anterior chamber of the eye – which contain the structures needed to maintain safe levels of intraocular pressure, Dr. Quaggin stated in a progress update. “We are excited to begin to test compounds in preclinical studies.”

Label Expansion Potential

In fact, Angpt-Tie2/TEK signaling plays a pivotal role in vascular development throughout the body. Expansion potential for this technology platform lies in a spectrum of vascular disease indications such as related macular degeneration and cystic kidney disease among others.

Other Potential Asset Acquisitions

Q BioMed is currently conducting due diligence on numerous BioMedical assets to expand its pipeline and build shareholder value. One such potential target under review is a fully-accommodative implantable ocular lens which needs funding to provide a proof of concept. The acquisition would give Q BioMed an additional ophthalmology asset in the pipeline.

Additional assets under review for 2016 include a Rare Orphan/Tropical Disease Drug stalled in the development stage due to lack of funding. The market for this drug includes 200 million patients.


Denis CorinPresident and Director

Denis Corin is an experienced public company executive and management consultant. He has worked almost exclusively in the biomedical field for over 13 years from large pharma and diagnostic companies to small innovative biotech. He has served in various senior executive roles and has been instrumental is building and restructuring businesses. Mr. Corin has raised millions of dollars in development capital to advance businesses. He also served as a Management Consultant to the executives and board of TapImmune, a clinical stage immune-oncology company until December 2015 where he had also previously served as CEO, CFO and President. Mr. Corin was a Director of TapImmune, from July 2009 to May 2012. He holds a Bachelor’s Degree majoring in both Economics and Marketing & Advertising Management from the University of Natal, South Africa.

William RosenstadtGeneral and Corporate Securities Counsel, Director

William Rosenstadt is the founding and managing partner of Sanders Ortoli Vaughn-Flam Rosenstadt LLP an international law firm located in New York and has been a practicing attorney since 1995. He advises entrepreneurs, public companies, and other corporate entities with respect to the execution of complex commercial, corporate, and international transactions. Rosenstadt and his firm are authorized to sponsor issuers on the OTC Markets as Principal American Liaisons and Designated Advisors for Disclosure and were instrumental in introducing the Canadian Securities Exchange to the OTC Markets and having it designated as an authorized exchange. Early in his legal career, he was general counsel to American Industrial Acquisition Corporation, a private equity firm focused on investing in privately held, middle market manufacturers in the wire/cable and defense industries. Rosenstadt graduated from Syracuse University with a B.A. in 1990 and received his J.D. from the Benjamin N. Cardozo School of Law in 1995. Further, he is admitted to the bars of New York, New Jersey, and Connecticut as well as the Second Circuit of the federal courts of the United States.

Ari JatwesCorporate Advisor and Senior Analyst

Ari Jatwes is an analyst and a banker, with over twenty years of experience. He began his career in a large accounting firm, progressing to a reputable investment bank, where he gained his tremendous experience in mergers and acquisitions. Over the last decade Jatwe’s interest and focus has been in the biotech and pharma sector, which included trading biotech stocks from start up to late stage biotech companies, advising management and raising capital for their needs. He has played an integral role in several successful contracts and transactions in the healthcare space – with emphasis on the life sciences and immunotherapy. Jatwes holds two Master degrees and a Bachelor Degree from the University of South Africa and the University of Natal.

David Laskow-PooleyVP Scientific and Product Development

David Laskow-Pooley has 30 years of experience in all aspects of the discovery, development and commercialization of pharmaceutical products, diagnostics and devices. He is an industry veteran and has a distinguished career working for numerous pharmaceutical and life sciences companies. Laskow-Pooley has held director, executive officer and general management posts in both small and major multinational companies including GSK, Abbott, Amersham plc, Life Technologies, OSI, Bilcare and Surface Therapeutics.

Advisory Board

Wombat Capital Ltd

Andy Watson

Senior Advisor: Diagnostics, Companion Diagnostics, Genomics and Life Science Tools

Dr. Geert Cauwenbergh

Senior Advisor: Skin Care, Dermatology, Wound Care, OTC, Infectious Diseases, Women’s Health

Dr. Helga Grupe

Senior Advisor: Oncology

Dr. Jose de Chastonay

Senior Advisor:ContractServices

Dr. Scott P Bruder

Senior Advisor: Medical Device Orthopedics and Regenerative Medicine

John Erb

Senior Advisor: Medical Device Cardio Vascular


Senior Advisor: Opthamology

Mannin Research Inc

Dr. Susan Quaggin

Director of the Feinberg Cardiovascular Research Institute at Northwestern University in Chicago

George Nikopoulos


Request an Investor Kit: Q BioMed

By completing this form, you are giving consent to receive email from Q BioMed. And remember you can unsubscribe at any time.

Enter Your Log In Credentials

Privacy & Legal Policy

This website is part of the Investing News Network published by Dig Media Inc.


INN's mission is to be the world's number one source of independent, unbiased news and education helping investors realized their financial goals. We also strive to be internationally respected for our integrity, our people and our commitment to excellence. Therefore, we are very concerned with the privacy rights of our audience and are committed to protecting the information collected about you.We have taken extensive measures to protect the confidentiality of your personal information and to protect your data from misuse and unauthorized access or disclosure. Unfortunately, no data transmission over the Internet can be guaranteed to be 100% secure. As a result, Dig Media cannot ensure or warrant the security of the information you transmit to us and you do so at your own risk.

Contact Information

Our postal address is

L200 - 560 Beatty Street,

Vancouver, BC V6B 2L3

We can be reached via e-mail at or telephone at +1-604-688-8231

Information Collected

For each visitor to our website, our web server automatically recognizes no information regarding the domain or e-mail address.

We collect information volunteered by the visitor, such as survey information and/or site registrations, name and address, telephone number.

The information we collect is used to notify visitors about updates to our website, shared with other reputable organizations to help them contact visitors for marketing purposes.

With respect to cookies: When you visit our websites, we send one or more cookies, a small file containing a string of characters, to your computer that uniquely identifies your browser during your visit. We use these cookies to maintain your connection as you move from page to page, and to ensure anything you submit, such as a comment or a form, is not rejected. You can reset your browser to refuse all cookies or to indicate when a cookie is being sent. However, some website features or services may not function properly without cookies.

If you do not want to receive e-mail from us in the future, please let us know by sending us e-mail at the above address.

Persons who supply us with their telephone numbers on-line may receive telephone contact from us with information regarding new products and services or upcoming events. If you do not wish to receive such telephone calls, please let us know by sending us e-mail at the above address.

Ad Server

With respect to Ad Servers:

Other third-party companies which place advertising on our site may collect information about you when you view or click on their advertising through the use of their cookies or other tracking technologies, which may include delivering targeted advertisements and marketing messages based upon the third party websites that you visit, or other purposes. We cannot control this collection of information and are not responsible for the privacy policies and data collection, use and disclosure practices of these third party advertisers. You should contact these third party advertisers directly if you have any questions about their use of the information that they collect from you. Google-DoubleClick DFP is our third party ad server. If you would like to know more about their information gathering practices and opt-out procedures, please see Google ad policies.

Also, if you would like more information about this practice and to know your choices about not having this information used by these companies, please see NAI Opt-out Options.

Information Use

We only share personal information with other companies or individuals outside of the cases outlined above in the following limited circumstances:

We may share with third parties certain pieces of aggregated, non-personal information, such as the number of users who searched for a particular term, for example, or how many users clicked on a particular advertisement. Such information does not identify you individually.


We may remarket your information. Remarketing is a way for us to connect with users, based upon your past interactions with INN websites. Third-party marketing vendors may be hired by INN to perform remarketing services. As a result, third-party vendors, including Google, may show INN ads on sites on the internet. Third-party vendors, including Google, use cookies to serve ads based on a user's prior visits to INN websites.

To opt out of customized Google Display Network ads click here. To find out more about how Google uses any data it collects please visit
Any information collected is used only for remarketing purposes and will not be used by them for any other purpose.

Future Use

From time to time, we may use visitor information for new, unanticipated uses not previously disclosed in our privacy notice. If our information practices change at some time in the future we will post the policy changes to our website to notify you of these changes and provide you with the ability to opt out of these new uses. If you are concerned about how your information is used, you should check back at our website periodically.

Accessing Your Data

Please contact us at the address above for any additional questions about the management or use of personal data.

Upon request we provide site visitors with access to communications that the visitor has directed to our site (e.g., e-mails, customer inquiries), contact information (e.g., name, address, phone number) that we maintain about them.

Visitors can access this information by e-mailing us at the above address.

Upon request we offer visitors the ability to have inaccuracies corrected in contact information.

Visitors can have this information corrected by sending us e-mail at the above address.


With respect to security: We have appropriate security measures in place in our physical facilities to protect against the loss, misuse or alteration of information that we have collected from you at our site.

Your Acceptance of These Terms

By using this site, or by submitting personal information to us, you signify your agreement to Dig Media's Privacy Policy and Terms of Use. From time to time we may change or update our piracy policies. It is your responsibility to check back regularly to inform yourself of such changes. Your continued use of this or any Dig Media website following the posting of changes to these terms will be deemed as your acceptance of those changes.

The foregoing policies are in effect as of August 1, 2012. Dig media reserves the right to change this policy statement at any time by posting the revised policy to this website. This statement and the policies outlined herein are not intended to and do not create any contractual or other legal rights in or on behalf of any party.

If you feel that this site is not following its stated information policy, you may contact us at the above addresses or phone number.

Investing News Network